In this episode of SARC Talk, we welcome Dr. Sandra D’Angelo, MD and Dr. Andrea Napolitano, MD, to discuss Clear Cell Sarcoma (CCS) and the international collaboration behind SARC045, a Phase II study of tebentafusp in HLA-A2 patients with advanced CCS. The conversation explores their career paths into sarcoma, what makes Clear Cell Sarcoma biologically unique, how patient advocacy helped shape the trial, and why partnering with SARC was key to launching this study across the US and UK.